Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649426 · ClinicalTrials.gov registry record · NA
A Study of the ReCor Medical Paradise System in Clinical Hypertension
A NA study of Hypertension and Vascular Diseases, sponsored by ReCor Medical.
- Active
- Registry status
- NA
- Development phase
- 282
- Enrollment target
- 20
- Study locations
NCT02649426: Active NA study of Hypertension and Vascular Diseases, sponsored by ReCor Medical.
NCT02649426 is a NA study of Hypertension and Vascular Diseases that is active but no longer recruiting, run by ReCor Medical. The registered enrollment target is 282 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02649426, a NA study of Hypertension and Vascular Diseases, is active but no longer recruiting, sponsored by ReCor Medical.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 282 participants
- Enrollment target
- 20
- Study locations
Study Summary
RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct populations of hypertensive subjects.
Primary Outcome
Mean difference in average daytime ambulatory systolic BP of the Solo cohort
Conditions Studied
Interventions
- DEVICE Sham Procedure
- DEVICE The Paradise® Renal Denervation Ultrasound System
Study Locations (20)
California
- Cedars-Sinai Medical Center - Los Angeles
- Sutter Health Medical Center - Sacramento
Massachusetts
- Massachusetts General Hospital - Boston
- The Brigham and Women's Hospital - Boston
New York
- New York University School of Medicine - New York
- Columbia University / NewYork Presbyterian Hospital - New York
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Cleveland Clinic - Cleveland
Alabama
- University of Alabama at Birmingham - Birmingham
Connecticut
- Stamford Hospital - Stamford
Florida
- The Cardiac and Vascular Institute - Gainesville
Georgia
- Emory University Hospital Midtown - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2016-03 |
| Est. Completion | 2025-05 |
| Phase | NA |
What the registry record for NCT02649426 still lists
NCT02649426 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Sham Procedure is the first listed.
NCT02649426 names 20 study sites across 16 states, led by California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT02649426 about?
NCT02649426 is a clinical study titled "A Study of the ReCor Medical Paradise System in Clinical Hypertension". RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct populations of hypertensive subjects.
What is the current status of trial NCT02649426?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 282 participants. The study started on 2016-03. Estimated completion is 2025-05.
What conditions does trial NCT02649426 study?
This clinical trial studies the following conditions: Hypertension, Vascular Diseases.
What interventions are being tested in trial NCT02649426?
The interventions under investigation include: Sham Procedure (DEVICE), The Paradise® Renal Denervation Ultrasound System (DEVICE).
Who is sponsoring clinical trial NCT02649426?
This trial is sponsored by ReCor Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02649426 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02649426's enrollment target sits among peer trials
282 185th of 470 higher than 286 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
How a Mediterranean Diet With Potatoes Impacts Heart and Metabolic Health in Adults With Pre-Diabetes
RECRUITING · NA
-
Conical Forearm and Cylindrical Upper Arm Non-Invasive Blood Pressure (NIBP) Measurements in Pregnant Patients
RECRUITING · NA
-
Comparing Healthcare Visit Recording and Open Notes to Improve Chronic iLlness Care Experience in Older Adults
RECRUITING · NA
-
Early Time-Restricted Eating in Older Adults With Hypertension
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia